Table 4.
Associations with COVID-19 infection severity in the full sample including all eligible individuals for sotrovimab treatment.
| Predictors |
Sotrovimab |
Controls |
Severe/critical/fatalaCOVID-19 vs. mild/asymptomatic infection |
|||||
|---|---|---|---|---|---|---|---|---|
| Total sample | Severe/critical/fatalaCOVID-19 | Total sample | Severe/critical/fatalaCOVID-19 |
Univariable regression analysis |
Multivariable regression analysis |
|||
| N (%) | N (%b) | N (%) | N (%b) | OR (95% CI) | P-value | AOR (95% CI) | P-value | |
| Study group | ||||||||
| Control | - | - | 2,845 (100.0) | 10 (0.4) | 1.00 | 1.00 | ||
| Sotrovimab | 519 (100.0) | 9 (1.7) | - | - | 5.00 (2.02-12.37) | <0.001 | 1.80 (0.61-5.29) | 0.288 |
| Vaccination statusc | ||||||||
| Unvaccinated | 153 (29.5) | 4 (2.6) | 658 (23.1) | 5 (0.8) | 1.00 | 1.00 | ||
| Two doses | 298 (57.4) | 4 (1.3) | 1,655 (58.2) | 4 (0.2) | 0.37 (0.14-0.95) | 0.040 | 0.51 (0.17-1.57) | 0.242 |
| Three doses | 68 (13.1) | 1 (1.5) | 532 (18.7) | 1 (0.2) | 0.30 (0.06-1.38) | 0.122 | 0.35 (0.06-1.88) | 0.219 |
| Prior infection statusc | ||||||||
| No | 478 (92.1) | 9 (1.9) | 2,605 (91.6) | 10 (0.4) | 1.00 | 1.00 | ||
| Yes | 41 (7.9) | 0 (0.0) | 240 (8.4) | 0 (0.0) | 1.00 (1.00-1.00) | - | 1.00 (1.00-1.00) | - |
| Age (years) | ||||||||
| <40 | 199 (38.3) | 2 (1.0) | 1,419 (49.9) | 5 (0.4) | 1.00 | 1.00 | ||
| 40-59 | 204 (39.3) | 2 (1.0) | 1,357 (47.7) | 3 (0.2) | 0.74 (0.23-2.34) | 0.607 | 0.81 (0.24-2.70) | 0.728 |
| ≥60 | 116 (22.4) | 5 (4.3) | 69 (2.4) | 2 (2.9) | 9.05 (3.14-26.10) | <0.001 | 5.68 (1.63-19.77) | 0.006 |
| Sex | ||||||||
| Male | 215 (41.4) | 4 (1.9) | 1,071 (37.6) | 4 (0.4) | 1.00 | 1.00 | ||
| Female | 304 (58.6) | 5 (1.6) | 1,774 (62.4) | 6 (0.3) | 0.85 (0.34-2.12) | 0.728 | 0.75 (0.28-1.98) | 0.558 |
| Nationality | ||||||||
| Qatari | 159 (30.6) | 3 (1.9) | 1,337 (47.0) | 3 (0.2) | 1.00 | 1.00 | ||
| Craft and manual worker nationalitiesd | 144 (27.7) | 2 (1.4) | 627 (22.0) | 0 (0.0) | 0.65 (0.13-3.21) | 0.593 | 0.70 (0.13-3.72) | 0.678 |
| Other nationalities | 216 (41.6) | 4 (1.9) | 881 (31.0) | 7 (0.8) | 2.52 (0.93-6.82) | 0.070 | 1.91 (0.65-5.60) | 0.240 |
| Comorbidity count | ||||||||
| None | 58 (11.2) | 0 (0.0) | 312 (11.0) | 4 (1.3) | 1.00 | 1.00 | ||
| 1 | 186 (35.8) | 3 (1.6) | 1,662 (58.4) | 5 (0.3) | 0.40 (0.12-1.33) | 0.134 | 1.13 (0.29-4.41) | 0.864 |
| 2 | 167 (32.2) | 1 (0.6) | 693 (24.4) | 1 (0.1) | 0.21 (0.04-1.17) | 0.075 | 0.43 (0.06-2.82) | 0.377 |
| ≥3 | 108 (20.8) | 5 (4.6) | 178 (6.3) | 0 (0.0) | 1.61 (0.43-6.12) | 0.471 | 2.47 (0.44-13.85) | 0.302 |
| Epidemic phasee | ||||||||
| Delta-dominated incidence | 198 (38.2) | 4 (2.0) | 262 (9.2) | 5 (1.9) | 1.00 | 1.00 | ||
| Omicron-dominated incidence | 321 (61.8) | 5 (1.6) | 2,583 (90.8) | 5 (0.2) | 0.17 (0.07-0.43) | <0.001 | 0.35 (0.13-0.96) | 0.041 |
Abbreviations: AOR, adjusted odds ratio; OR, odds ratio.
Severity (2021), criticality (2021), and fatality (2021) were defined according to the World Health Organization guidelines.
Proportion of those who progressed to severe, critical, or fatal COVID-19 among those in the predictor category.
Vaccination status and prior infection status were ascertained at the time of infection.
These include Bangladeshis, Indians, Nepalese, Pakistanis, Sri Lankans, and Sudanese due to large proportions of these nationals being craft and manual workers.
Before December 19, 2021 incidence in Qatar was dominated by the Delta variant, whereas starting from December 19, 2021 incidence was dominated by the Omicron variant.